Patents by Inventor Laird Bloom

Laird Bloom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240117030
    Abstract: The present invention relates to antibodies that specifically bind to one or more of IL-4, IL-13, IL-33, TSLP, and p40. The present invention further relates to antibodies that bind to one of IL-4, IL-13, IL-33, or TSLP. The invention further relates to multispecific antibodies that specifically bind to IL-4 and IL-13, and at least one other target. The present invention relates to multispecific antibodies that bind IL-4, IL-13, and one of IL-33, TSLP, or p40. The present invention also pertains to related molecules, e.g. nucleic acids which encode such antibodies or multispecific antibodies, compositions, and related methods, e.g., methods for producing and purifying such antibodies and multispecific antibodies, and their use in diagnostics and therapeutics.
    Type: Application
    Filed: February 28, 2023
    Publication date: April 11, 2024
    Inventors: Rita Diane AGOSTINELLI, James Reasoner APGAR, Eric Matthew BENNETT, Laird BLOOM, Ting CHEN, Aaron Michael D'ANTONA, Arnab DE, Fang JIN, Marion Teresa KASAIAN, Matthew Allister LAMBERT, Kimberly Ann MARQUETTE, Virginie MCMANUS, Jessica Haewon MIN DEBARTOLO, Nicole Melissa PICHE-NICHOLAS, Richard Thomas SHELDON, Lioudmila TCHISTIAKOVA, Alexander Michael Shuford BARRON, Richard Lee GIESECK, III, Xiaotian ZHONG
  • Publication number: 20240059799
    Abstract: The present invention discloses an isolated antibody that specifically binds to TL1A, comprising a heavy chain variable region (TL1A-VH) and a light chain variable region (TL1A-VL), comprising the CDR-H1, CDR-H2, and CDR-H3 sequences of a TL1A-VH sequence selected from the group consisting of SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 57, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 89, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 110, SEQ ID NO: 120; and the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 18.
    Type: Application
    Filed: May 9, 2023
    Publication date: February 22, 2024
    Applicants: Pfizer Inc., Bristol-Myers Squibb Company
    Inventors: James Reasoner APGAR, Laird BLOOM, Fang JIN, Fridrik KARLSSON, Kimberly Ann MARQUETTE, Jessica Haewon MIN DEBARTOLO, Nicole Melissa PICHE-NICHOLAS, Lioudmila TCHISTIAKOVA
  • Publication number: 20240052047
    Abstract: The present invention relates to antibodies that specifically bind to one or both of IL27RA and gp130. The present invention further relates to bispecific antibodies that specifically bind to IL27RA and gp130. The present invention also pertains to related molecules, e.g. nucleic acids which encode such antibodies or bispecific antibodies, compositions, and related methods, e.g.
    Type: Application
    Filed: August 1, 2023
    Publication date: February 15, 2024
    Inventors: Yijie GAO, Nicholas Andrew MARZE, Laird BLOOM
  • Publication number: 20200308272
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to IL-33, as well as uses, and associated methods thereof.
    Type: Application
    Filed: December 29, 2019
    Publication date: October 1, 2020
    Inventors: Laird BLOOM, Karl Henry NOCKA, James Reasoner APGAR, Matthew Allister LAMBERT, Mark A. FARMER
  • Patent number: 10544212
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to IL-33, as well as uses, and associated methods thereof.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: January 28, 2020
    Assignee: Pfizer Inc.
    Inventors: Laird Bloom, Karl Henry Nocka, James Reasoner Apgar, Matthew Allister Lambert, Mark A. Farmer
  • Publication number: 20180155452
    Abstract: Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the P-cadherin tumor cell associated antigen and the CD3 T cell antigen.
    Type: Application
    Filed: December 13, 2017
    Publication date: June 7, 2018
    Applicant: Pfizer Inc.
    Inventors: Chad Michael May, Adam Reid Root, William A. Brady, Lioudmila Gennadievna Tchistiakova, Lidia Mosyak, Laird Bloom, Paul A. Moore, Leslie S. Johnson
  • Publication number: 20180037644
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to IL-33, as well as uses, and associated methods thereof.
    Type: Application
    Filed: April 24, 2017
    Publication date: February 8, 2018
    Inventors: Laird BLOOM, Karl Henry NOCKA, James Reasoner APGAR, Matthew Allister LAMBERT, Mark A. FARMER
  • Patent number: 9884921
    Abstract: Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the P-cadherin tumor cell associated antigen and the CD3 T cell antigen.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: February 6, 2018
    Assignee: Pfizer Inc.
    Inventors: Chad Michael May, Adam Reid Root, William A. Brady, Lioudmila Gennadievna Tchistiakova, Lidia Mosyak, Laird Bloom, Paul A. Moore, Leslie S. Johnson
  • Publication number: 20160207991
    Abstract: The present invention relates to antibodies that bind brain-derived neurotrophic factor (BDNF). The invention further relates to nucleic acid sequences coding for such antibodies. The present invention also relates to immunoconjugates comprising the antibodies of the invention and pharmaceutical compositions comprising the antibodies and/or the immunoconjugates. The present invention further relates to methods for treating pain and medical uses relating thereto.
    Type: Application
    Filed: September 1, 2015
    Publication date: July 21, 2016
    Applicant: PFIZER INC.
    Inventors: Laird Bloom, Qingcong Lin, Heather Hongrong Shih, Ying Sun, Orla Margaret Cunningham, William James Jonathan Finlay
  • Publication number: 20160002357
    Abstract: Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the P-cadherin tumor cell associated antigen and the CD3 T cell antigen.
    Type: Application
    Filed: June 26, 2015
    Publication date: January 7, 2016
    Applicant: PFIZER INC.
    Inventors: Chad Michael MAY, Adam Reid ROOT, William A. BRADY, Lioudmila Gennadievna TCHISTIAKOVA, Lidia MOSYAK, Laird BLOOM, Paul A. MOORE, Leslie S. JOHNSON
  • Publication number: 20120276102
    Abstract: The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods of using them. The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing, treating, and/or preventing IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, and other immune system disorders.
    Type: Application
    Filed: May 14, 2012
    Publication date: November 1, 2012
    Applicant: WYETH LLC
    Inventors: Laird BLOOM, Davinder GILL, Yulia VUGMEYSTER, Deborah A. YOUNG, Margot O'TOOLE, Heath M. GUAY, Karissa K. ADKINS, Amy Arlene WEAVER, Sadhana JAIN, Maya ARAI
  • Publication number: 20120264919
    Abstract: The present invention provides binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing and/or treating IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.
    Type: Application
    Filed: April 23, 2012
    Publication date: October 18, 2012
    Applicants: MEDIMMUNE LIMITED, WYETH LLC
    Inventors: Laird BLOOM, Davinder GILL, Yulia VUGMEYSTER, Deborah A. YOUNG, David LOWE, Viia VALGE-ARCHER
  • Publication number: 20120121505
    Abstract: The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2.
    Type: Application
    Filed: January 12, 2012
    Publication date: May 17, 2012
    Inventors: Davinder Singh Gill, Laird Bloom, Maximillian T. Follettie, Fionnuala McAleese, Sreekumar Kodangattil, John Francis DiJoseph, Nitin K. Damle, Peter R. Baum, Peter A. Thompson, John C. Kumer, Alan F. Wahl, Paul A. Algate, Sateesh Kumar Natarajan
  • Patent number: 8178097
    Abstract: The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods of using them. The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing, treating, and/or preventing IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, and other immune system disorders.
    Type: Grant
    Filed: May 26, 2009
    Date of Patent: May 15, 2012
    Assignee: Wyeth LLC
    Inventors: Laird Bloom, Davinder Gill, Yulia Vugmeyster, Deborah A. Young, Margot O'Toole, Heath M. Guay, Karissa K. Adkins, Amy Arlene Weaver, Sadhana Jain, Maya Arai
  • Patent number: 8163884
    Abstract: The present invention provides binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing and/or treating IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.
    Type: Grant
    Filed: May 26, 2009
    Date of Patent: April 24, 2012
    Assignees: Wyeth LLC, MedImmune Limited
    Inventors: Laird Bloom, Davinder Gill, Yulia Vugmeyster, Deborah A. Young, David Lowe, Viia Valge-Archer
  • Publication number: 20100124764
    Abstract: The invention provides polynucleotide vectors and linkers and methods for designing and making single chain variable fragment (“ScFv”) libraries. The invention also provides polynucleotide vectors and linkers and methods for reformatting the ScFv library into Fab and IgG formats for high throughput production and screening.
    Type: Application
    Filed: September 25, 2009
    Publication date: May 20, 2010
    Applicant: Wyeth
    Inventors: Simon Evan Hufton, William James Jonathan Finlay, Ian David Broadbent, Laird Bloom
  • Publication number: 20100075329
    Abstract: The present invention provides human binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL21R), and uses therefore. The invention further provides methods to predict whether the binding proteins of the invention may take on agonistic activities in vivo and produce a cytokine storm. In addition, the invention provides methods for determining whether an anti-IL21R binding protein is a neutralizing anti-IL21R binding protein, based on the identification of several IL21-responsive genes. The binding proteins can act as, e.g., antagonists of IL21R activity, thereby modulating immune responses in general, and those mediated by IL21R in particular.
    Type: Application
    Filed: September 23, 2009
    Publication date: March 25, 2010
    Inventors: Margot O'Toole, Yongjing Guo, Renee Ramsey, Laird Bloom
  • Publication number: 20090304590
    Abstract: The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2.
    Type: Application
    Filed: October 27, 2008
    Publication date: December 10, 2009
    Applicants: Wyeth, Trubion Pharmaceuticals, Inc.
    Inventors: Davinder Singh Gill, Laird Bloom, Maximillian T. Follettie, Fionnuala McAleese, Sreekumar Kodangattil, John Francis DiJoseph, Nitin K. Damle, Peter R. Baum, Peter A. Thompson, John C. Kumer, Alan F. Wahl, Paul A. Algate, Sateesh Kumar Natarajan
  • Publication number: 20090298167
    Abstract: The present invention provides binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing and/or treating IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.
    Type: Application
    Filed: May 26, 2009
    Publication date: December 3, 2009
    Applicants: WYETH, MEDIMMUNE LIMITED
    Inventors: Laird BLOOM, Davinder GILL, Yulia VUGMEYSTER, Deborah A. YOUNG, David LOWE, Viia VALGE-ARCHER
  • Publication number: 20090298081
    Abstract: The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods of using them. The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing, treating, and/or preventing IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, and other immune system disorders.
    Type: Application
    Filed: May 26, 2009
    Publication date: December 3, 2009
    Applicant: WYETH
    Inventors: Laird BLOOM, Davinder GILL, Yulia VUGMEYSTER, Deborah A. YOUNG, Margot O'TOOLE, Heath M. GUAY, Karissa K. ADKINS, Amy Arlene WEAVER, Sadhana JAIN, Maya ARAI